OncoImmunity teams up with an innovative China based high-tech biotechnology company that has developed a dendritic cell-based vaccine delivery platform. The Chinese vaccine company is developing a personalized cancer vaccine solution with its platform that promises to deliver potent anti-tumor immune responses in vaccinated patients.
The collaboration will demonstrate the power of the Immuneoprofiler™ to predict accurate neoantigen targets for alleles that have high frequency in the human population, but little data in the publicly available databases. Such collaborations therefore demonstrate the ability of the Immuneoprofiler™ platform to guide personalized cancer immunotherapy for the Chinese and other Asian markets.
